Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great ChoiceZacks Investment Research • Thursday
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026Zacks Investment Research • Monday
A failed trial for a heart drug casts shadow over rivals developing similar therapiesMarket Watch • Monday
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol targetReuters • 11/02/26
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced ApproachSeeking Alpha • 10/31/26
4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialZacks Investment Research • 10/27/26
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues MissZacks Investment Research • 10/27/26
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity HitBenzinga • 10/27/26
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/27/26
Novartis Hikes Income Forecast, But There Were Caveats Within Its ReportInvestors Business Daily • 10/27/26
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis TranscriptSeeking Alpha • 10/24/26
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinibReuters • 10/23/26